OVERVIEW VIRUS DETECTION DATA ANALYSIS ORDERING AND SPECS RESOURCES
OVERVIEW

The Coronavirus pandemic led to a rapid response from the viral research and therapeutics community around the world. These research teams need robust and reliable genomic tools to classify and characterize viral samples. Twist offers Research-Use Only (RUO) NGS target enrichment panels for the detection and characterization of SARS-CoV-2 virus. The panel targets about 30 kb viral genome with approximately 1,000 probes, designed against the SARS-CoV-2 genome (GenBank: MN908947.3).

detection
Highly sensitive detection
Detection of as little as 10 copies of viral material with a fold enrichment of >100,000
Sequencing
More sequence information
Coverage of > 99.9% of the genome at 1X or greater post enrichment
Ability to identify viral mutations
monitor
Use for environmental monitoring and surveillance
Assess viral evolution over time
Track strain origin and transmission patterns
When Detection Isn't Enough

Introducing the SARS-CoV-2 NGS Assay - RUO:  a highly sensitive nucleic acid hybridization capture-based research-use only assay used for the detection, characterization, and environmental monitoring of the SARS-CoV-2 virus. It utilizes Twist Bioscience’s unique ability to rapidly develop virus-specific panels by DNA synthesis, and Biotia’s comprehensive data analysis software and reporting capabilities (COVID-DX (v1.0)). 

  • Sensitive detection level as few as 800 viral copies per ml in each specimen 
  • Coverage of > 99.9% of the genome at 1X or greater post enrichment 
  • Ability to identify novel viral mutations 
  • RUO software analytics report provides variant typing and phylogenetic analysis for epidemiological surveillance  
     

Twist with Biotia analysis software

 

The Coronavirus pandemic led to a rapid response from the viral research and therapeutics community around the world. These research teams need robust and reliable genomic tools to classify and characterize viral samples. Twist offers Research-Use Only (RUO) NGS target enrichment panels for the detection and characterization of SARS-CoV-2 virus. The panel targets about 30 kb viral genome with approximately 1,000 probes, designed against the SARS-CoV-2 genome (GenBank: MN908947.3).

detection
Highly sensitive detection
Detection of as little as 10 copies of viral material with a fold enrichment of >100,000
Sequencing
More sequence information
Coverage of > 99.9% of the genome at 1X or greater post enrichment
Ability to identify viral mutations
monitor
Use for environmental monitoring and surveillance
Assess viral evolution over time
Track strain origin and transmission patterns
When Detection Isn't Enough

Introducing the SARS-CoV-2 NGS Assay - RUO:  a highly sensitive nucleic acid hybridization capture-based research-use only assay used for the detection, characterization, and environmental monitoring of the SARS-CoV-2 virus. It utilizes Twist Bioscience’s unique ability to rapidly develop virus-specific panels by DNA synthesis, and Biotia’s comprehensive data analysis software and reporting capabilities (COVID-DX (v1.0)). 

  • Sensitive detection level as few as 800 viral copies per ml in each specimen 
  • Coverage of > 99.9% of the genome at 1X or greater post enrichment 
  • Ability to identify novel viral mutations 
  • RUO software analytics report provides variant typing and phylogenetic analysis for epidemiological surveillance  
     

Twist with Biotia analysis software

 

VIRUS DETECTION

NGS for Virus Detection

Next-generation sequencing (NGS) offers high-throughput, specific identification of infections in a variety of sample types including blood, nasal swab, feces, etc. In the case of viral infections, however, direct sequencing can be a challenge due to the extremely low concentration of the viruses of interest and the presence of high background from the host. Target capture using DNA-based hybridization probes to isolate specific sequences out of a mixed genomic sample can increase the sensitivity and specificity of NGS-based efforts.

High Sensitivity Through Efficient Design

Twist’s highly sensitive and accurate target capture enables efficient viral RNA detection. We demonstrate target enrichment’s ability to capture and detect the viral genome at varying numbers of viral copies spiked into human reference RNA. At high viral load (approximately 1 million copies), the complete genome is recovered even with only 25,000 reads*. While at lower copy numbers, coverage of large portions of the viral template is maintained. No reads from the negative control map to the viral template even when using 8 million mapped reads, demonstrating our detection at 10 copies represents true capture and not background contamination. Find out more in the App Note.

*When using COVID-Dx, 1 million reads are necessary for analytics.

NGS SARS-CoV-2 Research Panel Genome Coverage
Easy Workflow from Purified RNA to Sequencing

The Twist SARS-CoV-2 Research Panel is provided with a simple-to-follow protocol from purified RNA samples to sequencing with easily available components.

NGS SARS-CoV-2 Research Panel Workflow

NGS for Virus Detection

Next-generation sequencing (NGS) offers high-throughput, specific identification of infections in a variety of sample types including blood, nasal swab, feces, etc. In the case of viral infections, however, direct sequencing can be a challenge due to the extremely low concentration of the viruses of interest and the presence of high background from the host. Target capture using DNA-based hybridization probes to isolate specific sequences out of a mixed genomic sample can increase the sensitivity and specificity of NGS-based efforts.

High Sensitivity Through Efficient Design

Twist’s highly sensitive and accurate target capture enables efficient viral RNA detection. We demonstrate target enrichment’s ability to capture and detect the viral genome at varying numbers of viral copies spiked into human reference RNA. At high viral load (approximately 1 million copies), the complete genome is recovered even with only 25,000 reads*. While at lower copy numbers, coverage of large portions of the viral template is maintained. No reads from the negative control map to the viral template even when using 8 million mapped reads, demonstrating our detection at 10 copies represents true capture and not background contamination. Find out more in the App Note.

*When using COVID-Dx, 1 million reads are necessary for analytics.

NGS SARS-CoV-2 Research Panel Genome Coverage
Easy Workflow from Purified RNA to Sequencing

The Twist SARS-CoV-2 Research Panel is provided with a simple-to-follow protocol from purified RNA samples to sequencing with easily available components.

NGS SARS-CoV-2 Research Panel Workflow
DATA ANALYSIS

Biotia Analysis

Twist SARS-CoV-2 Research Panel has been combined with additional reagents and analysis to create an end-to-end solution from sample collection through tertiary analytics, providing the SARS-CoV-2 NGS Assay.

The Biotia COVID-DX (v1.0) software provides a research-oriented report that includes the full sequence of the SARS-CoV-2 virus, enabling improved understanding of mutations, genetic variations, and the evolution of the virus as it is transmitted. FASTQ files (sequencing output) can be generated in laboratories and submitted to Biotia COVID-DX (v1.0), a cloud-based software, to generate research-use only reports. The purchase of each SARS-CoV-2 NGS Assay kit includes credits for COVID-DX (v1.0) bioinformatic analysis of each sample. 

To receive Biotia analysis credits, simply register through the Biotia User Portal via www.biotia.io and enter the unique order number emailed to you once you place your order. These credits provide access to run samples through the report generation component of the software.

Genetic variants identified

Genetic variants are determined by aligning the test strain to the SARS-CoV-2 reference genome (NC_045512.2) with information on gene location/site, alteration and literature notes if any. 

 

Detected SARS-CoV-2 Gene Site (bp) Alteration Reference value
Yes GORF1ab 241 T Not Detected
Yes ORF1ab 478 T Not Detected
Yes ORF1ab 3,037 T Not Detected
Yes ORF1ab 14408* T Not Detected
Yes ORF1ab 18877 T Not Detected
Yes S 23403 G Not Detected
Yes 3a 25563 T Not Detected
Yes 3’UTR 29759 C Not Detected

 

Sequence results mapped across the genome.

The percent of the SARS-CoV-2 genome recovered from your test sample, and genetic variants identified compared to the reference genome are indicated. The proportion of known genetic variants of SARS-CoV-2 strains from across the world are shown (bottom).

Sequence results mapped across the genome.
Phylogenetic analysis and surveillance monitoring.

The test sample is most closely related to Clade 20A

This clade is found with the highest frequency a mong sequenced samples in the United States, Belgium, and France

Phylogenetic analysis and surveillance monitoring.

Biotia Analysis

Twist SARS-CoV-2 Research Panel has been combined with additional reagents and analysis to create an end-to-end solution from sample collection through tertiary analytics, providing the SARS-CoV-2 NGS Assay.

The Biotia COVID-DX (v1.0) software provides a research-oriented report that includes the full sequence of the SARS-CoV-2 virus, enabling improved understanding of mutations, genetic variations, and the evolution of the virus as it is transmitted. FASTQ files (sequencing output) can be generated in laboratories and submitted to Biotia COVID-DX (v1.0), a cloud-based software, to generate research-use only reports. The purchase of each SARS-CoV-2 NGS Assay kit includes credits for COVID-DX (v1.0) bioinformatic analysis of each sample. 

To receive Biotia analysis credits, simply register through the Biotia User Portal via www.biotia.io and enter the unique order number emailed to you once you place your order. These credits provide access to run samples through the report generation component of the software.

Genetic variants identified

Genetic variants are determined by aligning the test strain to the SARS-CoV-2 reference genome (NC_045512.2) with information on gene location/site, alteration and literature notes if any. 

 

Detected SARS-CoV-2 Gene Site (bp) Alteration Reference value
Yes GORF1ab 241 T Not Detected
Yes ORF1ab 478 T Not Detected
Yes ORF1ab 3,037 T Not Detected
Yes ORF1ab 14408* T Not Detected
Yes ORF1ab 18877 T Not Detected
Yes S 23403 G Not Detected
Yes 3a 25563 T Not Detected
Yes 3’UTR 29759 C Not Detected

 

Sequence results mapped across the genome.

The percent of the SARS-CoV-2 genome recovered from your test sample, and genetic variants identified compared to the reference genome are indicated. The proportion of known genetic variants of SARS-CoV-2 strains from across the world are shown (bottom).

Sequence results mapped across the genome.
Phylogenetic analysis and surveillance monitoring.

The test sample is most closely related to Clade 20A

This clade is found with the highest frequency a mong sequenced samples in the United States, Belgium, and France

Phylogenetic analysis and surveillance monitoring.
Ordering and Specs
PRODUCT SKUS - LIBRARY PREP + REAGENTS + RESEARCH PANEL + BIOTIA

104796

Twist SARS-CoV-2 NGS Assay - RUO, 16 Samples

104797

Twist SARS-CoV-2 NGS Assay - RUO, 96 Samples

104799

Twist SARS-CoV-2 NGS Assay - RUO, 768 Samples
PRODUCT SKUS - RESEARCH PANEL + BIOTIA

103564

Twist SARS-CoV-2 Research Panel + Biotia COVID DX (v1.0) - RUO, 2 Reactions, Kit

103566

Twist SARS-CoV-2 Research Panel + Biotia COVID DX (v1.0) - RUO, 12 Reactions, Kit

103567

Twist SARS-CoV-2 Research Panel + Biotia COVID DX (v1.0) - RUO, 96 Reactions, Kit
PRODUCT SKUS – RESEARCH PANEL

102016

Twist SARS-CoV-2 Research Panel, 2 Reactions, Kit

102017

Twist SARS-CoV-2 Research Panel, 12 Reactions, Kit

102018

Twist SARS-CoV-2 Research Panel, 96 Reactions, Kit

The Twist Synthetic SARS-CoV-2 RNA Controls are for research use only, and subject to additional use restrictions as set forth in Twist’s Supply Terms and Conditions.

PRODUCT SKUS - LIBRARY PREP + REAGENTS + RESEARCH PANEL + BIOTIA

104796

Twist SARS-CoV-2 NGS Assay - RUO, 16 Samples

104797

Twist SARS-CoV-2 NGS Assay - RUO, 96 Samples

104799

Twist SARS-CoV-2 NGS Assay - RUO, 768 Samples
PRODUCT SKUS - RESEARCH PANEL + BIOTIA

103564

Twist SARS-CoV-2 Research Panel + Biotia COVID DX (v1.0) - RUO, 2 Reactions, Kit

103566

Twist SARS-CoV-2 Research Panel + Biotia COVID DX (v1.0) - RUO, 12 Reactions, Kit

103567

Twist SARS-CoV-2 Research Panel + Biotia COVID DX (v1.0) - RUO, 96 Reactions, Kit
PRODUCT SKUS – RESEARCH PANEL

102016

Twist SARS-CoV-2 Research Panel, 2 Reactions, Kit

102017

Twist SARS-CoV-2 Research Panel, 12 Reactions, Kit

102018

Twist SARS-CoV-2 Research Panel, 96 Reactions, Kit

The Twist Synthetic SARS-CoV-2 RNA Controls are for research use only, and subject to additional use restrictions as set forth in Twist’s Supply Terms and Conditions.

RESOURCES
Don’t Settle For Less
Don’t Settle For Less
Don’t Settle For Less